None listed
Conditions
Brief summary
The aim of this study is to determine the suitability and safety of an 18-week exercise program for people with brain cancer and to test whether the program improves quality of life, well-being and physical health. Who is it for? You may be eligible to join this study if you are aged 18 years or over and have a diagnosis of primary malignant brain tumour (i.e. brain cancer). Study details During the 18-week intervention, Accredited Exercise Physiologists (AEP) will prescribe weekly exercise that will be individualised according to the your interests, fitness, presence of treatment-related side effects and co-morbidities. The exercise program will include aerobic (cardiovascular) exercise, and resistance (strength) based exercise. The AEP will prescribe and monitor exercise type, duration and frequency every week and modify prescription according to symptoms and gradually progress the exercise prescription. You may choose to do all exercise sessions under the supervision of an AEP at Aspire Fitness and Rehabilitation (at Woolloongabba, Brisbane) or have some exercise sessions supervised and other unsupervised (at home or another convenient location). Assessments (questionnaires and physical assessments) will be conducted at baseline, the middle (week 9), the end of the of the program (week 18) and 6 months later. We hypothesise that participants will feasibly and safely participate in an 18-week individualised exercise intervention.
Interventions
The exercise intervention will span a total of 18-weeks and will involve individualised exercise prescription of aerobic-and resistance-based exercise at moderate-intensity with a goal of 150 minutes per week including 2-3 sessions of resistance exercise.
Although the target dose of exercise (150 minutes of moderate intensity activity) will be the same for all participants, the structure of the intervention, including the type, intensity and duration will be individualised according to each par
The exercise intervention will span a total of 18-weeks and will involve individualised exercise prescription of aerobic-and resistance-based exercise at moderate-intensity with a goal of 150 minutes per week including 2-3 sessions of resistance exercise. Although the target dose of exercise (150 minutes of moderate intensity activity) will be the same for all participants, the structure of the intervention, including the type, intensity and duration will be individualised according to each participant’s interests, fitness, presence of treatment-related side effects and co-morbidities. An accredited exercise physiologist (AEP) will prescribe and monitor exercise type, duration and frequency on a weekly basis and modify prescription according to presentation of symptoms and by adhering to the exercise principle of gradual progression. AEPs will complete a study logbook to record details about the exercise prescribed, exercise completed and presence of adverse events. The delivery of the intervention will involve a minimum of one AEP supervised session (approximately 60 minute duration) per week for the first 8 weeks, and one AEP supervised sessions (approximate duration of 30 minutes) per fortnight for weeks 9-18. Supervised AEP sessions will take place at Aspire fitness and rehabilitation (at Woolloongabba). Unsupervised exercise session will be conducted at the convenient to the participant (e.g. local park, at home). Additional support by way of additional supervised sessions and/or telephone contact will occur when needed (as determined by the AEP) or when desired (as determined by the participant). The AEP will speak to the participant (either in person during supervised sessions or over the telephone) at least once per week. The participant will be provided with printed (or emailed) copies of their exercise prescription including instructions.
Sponsors
Haematology & Oncology Clinics of Australia Research Centre Ltd (Trading as Icon Cancer Foundation)
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. People with a diagnosis of primary or recurrent malignant brain tumour (i.e. brain cancer e.g. gliomas (astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and mixed cell type gliomas)). Patients with recurrent brain cancer are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. . 2. Age 18 years or older 3. Eastern Cooperative Oncology Group (ECOG) status 0-2. 4. Willing and able to comply with all study requirements, including the exercise intervention, timing and/or nature of required assessments. 5. Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements. 6. Anticipated survival of a minimum of 12 months, as assessed by the treating clinician (e.g. medical oncologist, radiation oncologist, or surgeon). 7. If radiotherapy was received, they are between 12 and 26 weeks post-radiotherapy (receipt of oral chemotherapy during this period is allowed). 8. Signed written informed consent. 9. Deemed suitable to participate in the study by treating clinician.
Exclusion criteria
1. Diagnosis of secondary brain cancer, or brain cancer recurrence within the first two years of definitive primary treatment. 2. Diagnosis of central nervous system lymphoma. 3. History of another malignancy within 2 years prior to registration. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. Patients with a diagnosis of basal cell carcinoma and squamous cell carcinomas and pre-malignant carcinomas (e.g. in situ) are also eligible. 4. Concurrent illness, including severe infection or unstable angina that may jeopardise the ability of the patient to undergo the exercise intervention outlined in this protocol with reasonable safety. 5. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol, as determined by their treating clinician.
Outcome results
None listed